As­traZeneca CEO Pas­cal So­ri­ot taps vet­er­an can­cer re­searcher Su­san Gal­braith for top on­col­o­gy post

When Su­san Gal­braith joined the can­cer R&D team at As­traZeneca in 2010, the phar­ma gi­ant was un­der­go­ing a bru­tal take­down at the hands of an­a­lysts uni­form­ly shak­ing their heads over one of the weak­est pipelines among the ma­jors. Both she and the com­pa­ny per­se­vered, though, and went on to pi­o­neer some of the most suc­cess­ful drug fran­chis­es in on­col­o­gy.

To­day, she takes her place as the new EVP of on­col­o­gy re­search at As­traZeneca’s new re­search and de­vel­op­ment home in Cam­bridge, UK.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER